medigraphic.com
ISSN 0210-5187 (Electronic)

2010, Number 1

<< Back Next >>

Med Cutan Iber Lat Am 2010; 38 (1)

Allitretinoin and chronic eczema of hands

Alomar AA, Fernández VJM, Serra E, Manrique P

Language: Spanish
References: 20
Page: 23-32
PDF size: 175.77 Kb.


ABSTRACT

Hand eczema is a common dermatosis affecting the hands. Exposure to irritants, allergens and endogenous factors play interrelated roles in the aetiology of this disease. Consequently, it is rarely possible to identify all causative factors and remove them entirely.
In a substantial number of patients, hand eczema develops into a chronic condition even when an initial causative agent is avoided. In general, hand dermatitis is considered chronic if it lasts more than 6 months in the absence of external causal factors.
Patients with CHE suffer from painful cracks, blisters, itching and bleeding, which can limit manual dexterity and prevent employment. These types of patients with CHE have a poor prognosis; it is a self perpetuating condition with a long-lasting and chronically relapsing course.
Mild cases of CHE are usually managed with conscientious use of emollients and topical corticosteroids, and avoidance of irritants, but severe CHE is debilitating if it is refractory to this standard regimen. Severe CHE causes substantial occupational, functional, social and psychological disability, including prolonged sick leave and unemployment, anxiety, low self-esteem, and social phobia.
Currently patients with severe CHE refractory to topical corticosteroids have limited treatment options suited for chronic use, and few clinical trials have investigated new therapies in this setting. None of the current treatment options present an alternative to Alitretinoin for the treatment of refractory CHE.


REFERENCES

  1. Diepgen TL, Agner T, Aberer W, Berth-Jones J, Cambazard F, Elsner P, et al. Management of chronic hand eczema. Contact Dermatitis 2007; 57: 203-210.

  2. Meding B. Epidemiology of hand eczema in an industrial city. Acta Derm Venereol 1990; 153 (Supl.): 1-43.

  3. Diepgen TL, Coenraads PJ. The epidemiology of occupational contact dermatitis. Int Arch Occup Environ Health 1999; 72: 496–506.

  4. Van Coevorden AM, Coenraads PJ, Svensson A, Bavinck JN, Diepgen TL, Naldi L et al. Overview of studies of treatments for hand eczema – the EDEN hand eczema survey. Br J Dermatol 2004; 151: 446–51.

  5. Schluter-Wigger W, Elsner P. Efficacy of 4 commercially available protective creams in the repetitive irritation test (RIT). Contact Dermatitis 1996; 34: 278-83.

  6. Landow K. Hand Dermatitis. Post Graduate Medicine 1998; 103: 141.

  7. Berger TG, Duvic M, Van Voorhees AS, Van-Beek MJ. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Derm 2006; 54: 818-23.

  8. NICE Technology appraisal 82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) 2004 Available at: http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11538, Accessed on 03.03.08

  9. Arkavan A, Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clinics in Dermatology 2003; 21: 225-40.

  10. Granlund H, Erkko P, Reitamo S. Comparison of the influence of cyclosporin and topical betamethasone-17,21-dipropionate treatment on quality of life in chronic hand eczema. Acta Derm Venereol 1997; 77: 54–8.

  11. Geiger J, Hommel L, Harms M, Saurat JH. Oral 13-cis retinoic acid is superior to 9-cis retinoic acid in sebosuppression in human beings. J Am Acad Dermatol 1996; 34: 513-5.

  12. Ott F, Bollag W, Geiger JM. Oral 9-cis-retinoic acid versus 13-cis-retinoic acid in acne therapy. Dermatology 1996; 193: 124-6.

  13. Ruzicka T, Lynde CW, Jemec T, Diepgen T, Berth-Jones J, Coenraads PJ et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008; 158: 808-17.

  14. Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. Bissonnette R, Worm M, Gerlach B et al. Br J Dermatol 2009; 162: 420-6.

  15. Ruzicka T, Grønhøj Larsen F, Galewicz D et al. Oral Alitretinoin (9-cis-Retinoic Acid) Therapy for Chronic Hand Dermatitis in Patients Refractory to Standard Therapy. Arch Dermatol 2004;140: 1453-9.

  16. Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001; 144: 967-72.

  17. Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000; 84: 517-22.

  18. Grosshans E, Marks R, Mascaró JM, Torras H, Meynadier J, Alirezai M et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol. 1998; 139: 26-33.

  19. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-44.

  20. Basilea Pharmaceuticals DATA ON FILE reference sheet: COI-HE1 interim results: demographics and DLQI scores. Número de referencia: DOF-ALI08013. Datos del 16 de Septiembre de 2008.




2020     |     www.medigraphic.com